Currently, an individual’s risk of developing CVD can be assessed through their self-reported family history and lifestyle factors, such as physical activity levels, diet and smoking; however, this doesn’t consider their genetic susceptibility to CVDs.
When an individual is classed as an intermediate risk based on their lifestyle factors, it can be hard to determine if they will progress into developing CVDs, which is where genotyping could become extremely useful.
TYPE III Hyperlipoproteinemia, Atrial Fibrillation, Coronary Artery Disease, Hypertension, Myocardial Infarction, Peripheral Arterial Disease, Sickle Cell Anaemia.
Beta Blocker Efficiency, Beta Blockers and LVEF Response, Metoprolol metabolism, Warfarin sensitivity, Clopidogrel metabolism, Verapamil and QTC interval, Verapamil vs Atenolol, Simvastatin Uptake, Perindopril metabolism, caffeine sensitivity.
Triglycerides, HDL Cholesterol, LDL Cholesterol and Gene X (Cholesterol lowering polymorphism).
Factor V Leiden, prothrombin G20210A and MTHFR variant.
Patients with a family history of CVD.
Patients with existing cardiac conditions and would like to learn more about their conditions and their genetic risk profile concerning how they developed such conditions.
Patients who are on oestrogen therapy from combined oral contraceptives or hormone replacement therapy, or for patients with obesity, fractures, major orthopaedic surgery or with a family history of DVT.
Patients who are about to start medicating or currently on a treatment plan with reported side effects.
Anyone who would like to have a health check to know more about their heart health and to undertake further physical examinations whenever a high risk is identified.
Make mutual decisions based on trust, full understanding and a good communication before undertaking any examination or investigation, and before providing treatment. The reports enable you to strengthen your patients' informed consent by giving them full knowledge of the potential consequences regarding their lifestyle choices, treatment options and the possible risks and benefits.
The Heart DNA Test helps you suggest early interventions by identifying genetic risk factors for a range of conditions.
We also enable you to predict the risk of venous thrombosis by testing for Factor V Leiden, Prothrombin G20210A and the risk of arterial thrombosis by testing MTHFR gene for the predisposed levels of homocysteine and folate metabolism.
A positive patient experience is an important goal in its own right, including patient adherence to medical advice, better clinical outcomes and improved patient safety practices.
The evidence on using precision medicine in drug prescription has highlighted increased patient satisfaction and improved drug compliance due to a boost in confidence by patients using their prescribed treatment.
Our test would also help the practice to retain existing patients and improve patient loyalty, as well as attract new patients by offering a competitive advantage.
The Heart DNA Test is a reliable resource, with an accuracy rate of 99,8%. In combination with the test results, evidence-based genetic data and our extensive reference library we can help you make decisions that are specific to your patient's genetic makeup.
The final decision is always yours.
We support you for a more objective risk assessment combining the patient genetic risk profile and self-reported environmental risk factors.
Our genetic test supports your decision making when prescribing drugs with fewer side effects and ultimately reducing rehospitalisation rates.
Pharmacogenetics predicts patients’ drug response, reducing prescriptions of medication that is ineffective or causes adverse side effects.
In the case of warfarin, which is responsible for many adverse side effects, the genotyping of patients has been shown to reduce rehospitalisation rates.
In the case of clopidogrel, an antiplatelet drug, the US FDA added a boxed label to warn of reduced drug effectiveness if an individual's genotype to CYP2C9 renders the patient as a ‘‘poor metaboliser’’.
The Rightangled Platform designs a new way to personalise cardiac care by giving you access to genetic information alongside lifestyle and environmental risk factors of your patients. This information will help you build better risk profile of your patients while providing your assessment onto the report online.
The whole process is online. you can now create an account, fill in your speciality details, set your fees and access your dashboard for all our learning resources.
Place orders for your individual clients and manage your finances.
Access patient reports to make online assessments. Comment and sign off once the results are ready.
Patients can book appointments with you directly from their dashboard.
Reply instantly to patient concierge service via chat. Manage face to face and online patient consultations
The kit is barcoded with unique kit IDs that would be assigned to you. This will enable us to link your account with your patients'.
As an individual, you don't really care what happens to the rest of the population, unless it's about you specifically... Genomics Medicine lends itself to that
Dr. Sibtain Anwar
Cardiac Anaesthesia Consultant
We also provide you with a clinical reporting manual to review cumulative risk profile, and an on going support to answer all your questions from our network of leading geneticists.
We translate clinical research on genetics and FDA adopted interpretation guidelines into practical formats to help you build your personalised advice to your patient.
Shukla, H., Mason, J. L., & Sabyah, A. (2018). A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs. American Journal of Cardiovascular Drugs, 18(4), 259–269.
Shukla, H., Mason, J. L., & Sabyah, A. (2018). Identifying genetic markers associated with susceptibility to cardiovascular diseases. Future Science OA, https://doi.org/10.4155/fsoa-2018-0031
It's time of personalised medicineBecome a partner